Charlie Kim

Cooley advised Uber on its $8.1 billion initial public offering of 207,000,000 shares of common stock. Uber, whose securities now trade on the NYSE under the symbol “UBER,” is a mobility platform revolutionizing the personal ridesharing, meal delivery and logistics industries. Partners Dave Peinsipp, Siana Lowrey, Drew Williamson, Charlie Kim and Kristin VanderPas led the Cooley team.

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Cooley advised underwriters on 10X Genomics’ $448.5 million initial public offering of 11,500,000 shares of Class A common stock, including full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as joint book-running managers. Cowen acted as lead manager. 10X Genomics’ securities now trade on the Nasdaq Global Select Market under the symbol “TXG.” Partners Charlie Kim, Dave Peinsipp and Kristin VanderPas led the Cooley team.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.